Curevac wants to market own productsGerman biotech Curevac wants to market its own products and therefore to become a pharma company, founder and head of supervisory board Ingmar Hoerr told FAZ on Tuesday (p22).
Fresenius wins ruling on Akorn dealA U.S. court has said that German group Fresenius was allowed to pull out of €4.75 billion acquisition deal with U.S. generics manufacturer Akorn, causing Fresenius shares to rise briefly by more than 10%, Sueddeutsche Zeitung (SZ) wrote on Tuesday (p21) (APMHE 59951).
Stada to be delisted from German stock marketShares of generic and over-the-counter drug maker Stada will soon disappear from the German stock exchange after almost 21 years, wrote FAZ on Tuesday (p22) and Die Welt (p15) (APMHE 59959).
Continuity at PfizerAlbert Bourla, who was appointed to succeed Ian Read as Pfizer's CEO, is a guarantee of continuity for the U.S. pharma company, wrote Handelsblatt on Tuesday (p47) (APMHE 59940).
Pharma industry pays a lot for genetic dataPharma companies spend a lot of money to get genetic data by either investing in their own laboratories or buying the data from biotechs, Wirtschaftswoche reports on Friday (p66-69).
Mail-order pharmacies bigger than any German pharmacyMail-order pharmacies DocMorris and Shop Apotheke, which have moved their headquarters from Germany to the Netherlands, each have about 3 million customers and predicted sales of €500 million in 2018 - more than any pharmacy in Germany, Wirtschaftswoche writes on Friday (p54-56).
Nobel prizes for developers of artificial antibodies, cancer immunotherapiesU.S. researcher George Smith and British biochemist Gregory Winter, who are two of the three 2018 chemistry Nobel Prize winners, invented and developed the technique of "phage display of peptides and antibodies" that produced artificial antibodies such as world best-selling drug Abbvie's Humira (adalimumab), SZ wrote on Thursday (p14).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.